Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China,
Department of Pharmaceutics, 94th Hospital of People's Liberation Army, Nanchang, China.
Int J Nanomedicine. 2019 Jan 3;14:353-369. doi: 10.2147/IJN.S184374. eCollection 2019.
To improve the dissolution and bioavailability of poorly soluble drugs, novel nanosuspensions using co-processed nanocrystalline cellulose-sodium carboxymethyl starch (NCCS) as a synergetic stabilizer were first designed.
Co-processed NCCS was prepared by means of homogenization. Poorly soluble baicalin (BCA) was used as a model drug. BCA nanosuspension (BCA-NS/NCCS) using co-processed NCCS as a dispersant was prepared via homogenization and further converted into the dried BCA nanosuspension particle (BCA-NP/NCCS) via spray drying. The influence of NCCS on the dispersion efficiency of BCA-NS/NCCS was investigated. Morphology and crystal characteristic of NCCS and BCA-NP were analyzed. The dissolution and bioavailability evaluation were performed to investigate the feasibility of NCCS as a stabilizer for BCA-NS/NCCS and BCA-NP.
The optimum 50% concentration of NCCS (nanocrystalline cellulose [NCC]:sodium carboxymethyl starch [SCS]=60:40) could be mostly beneficial for formation and stability of BCA-NS/NCCS. NCCS could completely prevent aggregation of BCA-NP during spray drying and enhance the redispersibility as well as dissolution of spray-dried BCA-NP, which might be attributed to "brick-concrete"-based barrier effect of NCCS and the swelling capacity of superdisintegrant SCS. The crystal state of NCC and BCA presented in BCA-NP/NCCS remained unchanged during the homogenization. The BCA-NP/NCCS exhibited a fast dissolution rate and significantly enhanced bioavailability of BCA. The AUC of the BCA-NP/NCCS (8,773.38±718.18 µg/L·h) was 2.01 times (<0.05) as high as that of the crude BCA (4,354.61±451.28 µg/L·h).
This study demonstrated that novel surfactant-free nanosuspensions could be prepared using co-processed NCCS as a synergetic stabilizer and also provided a feasible strategy to improve the dissolution and oral bioavailability of poorly soluble drug.
为提高难溶性药物的溶解和生物利用度,首次设计了使用共处理纳米晶纤维素-羧甲基淀粉钠(NCCS)作为协同稳定剂的新型纳米混悬剂。
通过均化制备共处理 NCCS。以难溶性黄芩苷(BCA)为模型药物。通过均化制备使用共处理 NCCS 作为分散剂的 BCA 纳米混悬剂(BCA-NS/NCCS),并通过喷雾干燥进一步转化为干燥的 BCA 纳米混悬剂颗粒(BCA-NP/NCCS)。考察了 NCCS 对 BCA-NS/NCCS 分散效率的影响。分析了 NCCS 和 BCA-NP 的形态和晶体特性。进行了溶出度和生物利用度评价,以研究 NCCS 作为 BCA-NS/NCCS 和 BCA-NP 稳定剂的可行性。
NCCS 的最佳 50%浓度(纳米晶纤维素[NCC]:羧甲基淀粉[SCS]=60:40)最有利于 BCA-NS/NCCS 的形成和稳定性。NCCS 可完全防止喷雾干燥过程中 BCA-NP 的聚集,并增强喷雾干燥 BCA-NP 的再分散性和溶解能力,这可能归因于 NCCS 的“砖-混凝土”基屏障效应和超级崩解剂 SCS 的溶胀能力。NCCS 中 NCC 和 BCA 的晶体状态在 BCA-NP/NCCS 中保持不变。BCA-NP/NCCS 表现出快速的溶解速率,并显著提高了 BCA 的生物利用度。BCA-NP/NCCS 的 AUC(8,773.38±718.18 µg/L·h)是粗 BCA(4,354.61±451.28 µg/L·h)的 2.01 倍(<0.05)。
本研究表明,新型无表面活性剂纳米混悬剂可使用共处理 NCCS 作为协同稳定剂制备,并为提高难溶性药物的溶解和口服生物利用度提供了一种可行的策略。